Yayıncı "Elsevier Science Inc" Bildiri Koleksiyonu için listeleme
Toplam kayıt 10, listelenen: 1-10
-
Crizotinib efficacy in alk-positive advanced stage non-small cell lung cancer patients: A real-world experience from Turkey
(Elsevier Science Inc, 2018)Background: Increasing evidence leads to a ratiocination that genetic heterogeneity of the lung adenocarcinoma patients with sensitive EGFR mutations may impact clinical responses and outcomes to EGFR-TKIs. Method: We ... -
The difference between planned and delivered dose for head and neck cancer, and the consequences for normal tissue toxicity probability
(Elsevier Science Inc, 2018)Purpose/Objective(s): Anatomical changes during radiation for head andneck cancer (HNC) induce differences between the planned and delivereddose. To account for this, an adapted treatment plan can be designed. Thedecision ... -
Do manufacturer's derived recommendations predict vascular complications during transfemoral TAVI approaches using default proglide strategy
(Elsevier Science Inc, 2020)... -
Economic burden of gastric cancer in Turkey
(Elsevier Science Inc, 2017)Human papillomavirus (HPV) infection is a pre-requisite for vaginal and vulval cancers. The incidence of vaginal cancer in the UK has remained relatively stable over the past 25 years; however the age-standardised incidence ... -
Glass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients
(Elsevier Science Inc, 2021)Introduction: Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1(+) is still pending. ... -
Ibrutinib as a promising treatment for pulmonary complications due to refractory chronic graft versus host disease
(Elsevier Science Inc, 2020)Introduction: Despite major improvements in allogeneic hematopoetic stem cell transplantation form matched related/ unrelated donor over last decades, chronic graft-versus-host disease (cGVHD) is still the leading cause ... -
Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds
(Elsevier Science Inc, 2020)BACKGROUND The vast majority of clinical trials regarding bioresorbable vascular scaffold (BVS) use came from comparison of everolimus-eluting scaffolds with metallic stents, and it remains unclearwhether similar results ... -
Medically inoperable early-stage lung cancer treated with stereotactic ablative radiation therapy (SABR): Multicenter study of Turkish radiation oncology group (TROG)
(Elsevier Science Inc, 2018)Purpose/Objective(s): To review treatment outcomes for SABR inmedically inoperable early stage lung cancer (NSCLC) patients treated byTurkish Radiation Oncology Group (TROG) member centers.Materials/Methods:Between 2009 ... -
Outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical treatment
(Elsevier Science Inc, 2017)... -
Systemic inflammatory markers as a predictors of response to crizotinib in patients with ALK-positive non-small-cell lung cancer
(Elsevier Science Inc, 2019)The significance of the presence of a systemic inflammatory response (SIR) in predicting survival has been demonstrated in patients with cancer. Moreover, neutrophil-to-lymphocyte ratio (NLR), lymphocyteratio (NLR), ...